Startups
Alamar Biosciences
Fremont, California, United States
Alamar Biosciences, Inc. is a Fremont, California precision-proteomics technology company incorporated in Delaware in May 2018 and publicly traded on Nasdaq as ALMR following its April 2026 IPO. Its NULISA protein-detection assays and ARGO automated instruments measure very low-abundance proteins in small biological samples for biomedical research. The platform combines immunoassay engineering, molecular amplification and high-throughput readout, with analytical tools and an executive function for AI and strategic initiatives. Its neurological research products include CNS Disease and Neuro panels and assays for Alzheimer-associated brain-derived phosphorylated tau, neurofilament light and other protein biomarkers. These tools support neuroscience research and biomarker discovery; the published commercial products are for research use only and not for diagnostic procedures. An ARGO DX clinical-development programme and related planned regulatory submissions are distinct from current clearance. Research collaborations with the Alzheimer’s Disease Data Initiative and Gates Ventures do not by themselves establish equity investments. The Alzheimer’s Drug Discovery Foundation programme is a milestone-based research-funding commitment of up to USD10 million over 36 months, rather than USD10 million of cash paid upfront. Confirmed issuer fundraising includes the 2021 Series B, February 2024 Series C, January 2026 convertible notes and completed April 2026 IPO; prior preferred-share and note conversions at the IPO are not additional cash. Alamar founded Attovia Therapeutics and contributed platform intellectual property in exchange for equity, but distributed its remaining Attovia interest to shareholders in February 2024 and retained no Attovia shares following that transaction. Its current leadership includes co-founders Yuling Luo and Shiping Steve Chen, president Tod White, CFO Justin McAnear, CTO Xiao-Jun Ma, CSO Stephen Williams and a board that now includes former GRAIL CEO Bob Ragusa. Alamar is distinct from unrelated Alamar-branded entities and from its former therapeutic spinout.
Founded 2018
Team
 Alex Forrest-HaySenior Vice President of Sales |
Amelia MerrillChief People Officer |
 Anna BerdineSenior Vice President of Marketing |
 Daqing CaiFormer Director (historical Sherpa representative) |
 Frank R. WitneyLead Independent Director |
 Ian W. RatcliffeFormer Director (historical; deceased in 2026) |
 John BrottemGeneral Counsel |
 Justin McAnearChief Financial Officer |
 Micah LitowSenior Vice President, AI and Strategic Initiatives |
 Nicholas NaclerioDirector |
 Rebecca ChambersDirector |
Robert RagusaDirector |
 Shiping Steve ChenCo-founder, Chief Operating Officer and Director |
 Stephen WilliamsChief Scientific Officer |
 Timothy Tod WhitePresident |
 William HuFormer Director (historical Qiming representative) |
 Xiao-Jun MaChief Technology Officer |
 Yiyuan YinCo-founder and Vice President of Technology |
 Yuling LuoCo-founder, Chief Executive Officer and Chair |